Prosecution Insights
Last updated: November 04, 2026
Application No. 18/690,212

SKIN COMPOSITION INCLUDING EXTRACELLULAR VESICLES DERIVED FROM MALTED RICE

Non-Final OA §102
Filed
Oct 15, 2024
Priority
Sep 09, 2021 — JP 2021-146860 +1 more
Examiner
AL-AWADI, DANAH J
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Asahi Shuzo Co., Ltd.
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
449 granted / 823 resolved
-5.4% vs TC avg
Moderate +13% lift
Without
With
+13.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
39 currently pending
Career history
860
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
47.4%
+7.4% vs TC avg
§102
13.1%
-26.9% vs TC avg
§112
21.3%
-18.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 823 resolved cases

Office Action

§102
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s election with traverse of Group I in the reply filed on 9/15/2026 is acknowledged. The traversal is because both groups were searched and Examined during the examination of the corresponding PCT International Application. This is not found persuasive because each application is examined on its own merits and the lack of unity has been demonstrated in the restriction mailed 7/15/2026. The requirement is still deemed proper and is therefore made FINAL. Applicant is reminded that should all product claims be subsequently found allowable, withdrawn processes claims that include all the limitations of the allowable product will be considered for rejoinder. Claims 6-8 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group and Species, there being no allowable generic or linking claim. Election was made with traverse in the reply filed on 9/15/2026. INFORMATION DISCLOSURE STATEMENT 2. Information Disclosure Statements filed 7/26/2024, 5/8/2025, 10/31/2025, 12/4/2025, 8/7/2026 and 10/15/2026 are acknowledged. Claim Rejections- 35 USC § 102 3. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Asahi (WO 2020/158930 A1). Asahi (WO 2020/158930 A1) discloses an exosome extracted from yeast mash of sake or miso, used as a composition for skin (claims 3, 6, 18-19; " 0010, 0011, 0018, and 0022). Miso is soybean mixed with rice koji and salt and fermented. This anticipates the product of claim 1 and claims 2-5. With regards to claims 4 and 5, these claims are regarded as intended use of the composition and does not give patentable weight to the product. It must be noted that the recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In re Schreiber, 128 F.3d 1473, 1477, 44 USPQ2d 1429, 1431 (Fed.Cir. 1997) MPEP § 2111.02. In order to be limiting, the intended use must create a structural difference between the claimed composition and the prior art composition. CORRESPONDENCE 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danah Al-awadi whose telephone number is (571) 270-7668. The examiner can normally be reached on 9:00 am - 6:00 pm; M-F (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANAH AL-AWADI/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Oct 15, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778887
ALKALI METAL SALT COMBINATIONS OF INCOMPATIBLE ACTIVE PHARMACEUTICAL INGREDIENTS
3y 1m to grant Granted Nov 03, 2026
Patent 12766095
COMPOSITIONS FOR NASAL APPLICATION
3y 5m to grant Granted Oct 20, 2026
Patent 12766103
ANTICANCER COMPOSITIONS
2y 5m to grant Granted Oct 20, 2026
Patent 12751990
Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition
4y 6m to grant Granted Oct 06, 2026
Patent 12751970
Use of porous calcium-based granules for promoting healing of an intra-articular or peri-articular fracture of a fractured bone
2y 10m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
68%
With Interview (+13.2%)
3y 2m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 823 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month